EBV Breakthrough: New Research Could Prevent Cancer in Transplant Patients? | Science Finds Part 2

Can we vaccinate against Epstein-Barr Virus (EBV)Подробнее

50th anniversary of the EBV (Epstein-Barr Virus) link to cancer - Cancer Research UKПодробнее

Agent EBV: Helping the Immune System Fight CancerПодробнее

Burkitt lymphoma: a model of polymicrobial carcinogenesis and global oncologyПодробнее

Cytotoxic T lymphocyte cell therapy directed against EBV PTLD in the central nervous systemПодробнее

NZMSRT Webinar Epstein Barr VirusПодробнее

Vaccine breakthrough for EBV-associated cancers and MSПодробнее

"EBV at 50: still so much to learn!"Подробнее

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT trea...Подробнее

Ask an MS Expert: The Role of Epstein-Barr Virus in MSПодробнее

Breakthrough Science 2021Подробнее

Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD)Подробнее

EBV SpringboardПодробнее

Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLDПодробнее

Discerning the origin of Epstein-Barr virus in patients | Christopher OakesПодробнее

Mohamad Mohty, ASH 2018 – Epstein-Barr virus and cytotoxic T lymphocyte therapyПодробнее

Atara BiotherapeuticsПодробнее

Understanding the Challenge of EBV-Induced TumorsПодробнее